CD72 and acute lymphoblastic leukemia: Thus, direct protein study following our strategy of screening cDNA libraries, or the approach recently reported by Nix and colleagues39 using surface proteomics to define CD72 as a target for B-ALL, should become standard for defining innovative CAR targets.